Hepatoid adenocarcinoma of the lung with PD-L1 expression and the response to anti-PD-1 therapy: a case report

被引:1
|
作者
Li, Yan [1 ]
Liu, Lili [2 ]
Wang, Dongfeng [3 ]
Tan, Xiaojing [1 ]
Sui, Yanmin [1 ]
Yang, Honglan [1 ]
机构
[1] Dongying Peoples Hosp, Dept Oncol, Dongying, Shandong, Peoples R China
[2] Dongying Peoples Hosp, Dept Pathol, Dongying, Shandong, Peoples R China
[3] Dongying Peoples Hosp, Dept Chest Surg, Dongying, Shandong, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
hepatoid adenocarcinoma of the lung; alpha-fetoprotein; anti-PD-1; therapy; brain metastases; case report;
D O I
10.3389/fonc.2023.1257931
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hepatoid adenocarcinoma of the lung (HAL) is extremely rare; a standardized treatment strategy for HAL has not been established. The prognosis of patients with unresectable HAL is extremely poor. Here, we reported a 64-year-old male patient with unresectable alpha-fetoprotein-producing HAL who showed moderate harboring programmed death ligand 1 (PD-L1) expression and no targetable driver mutations. The patient was treated with brain radiotherapy, multiple lines of chemotherapies, and PD-1 inhibitor and achieved a survival rate of 9 months. The patient finally died because of the progression of brain metastasis. The case report provides valuable information for the treatment strategy development of advanced HAL patients and reminds us of the therapeutic particularity of brain metastasis.
引用
收藏
页数:4
相关论文
共 50 条
  • [41] Parameters of Tumor Microenvironment Determine Effectiveness of Anti-PD-1/PD-L1 Therapy
    Tashireva, Liubov A.
    Muravyova, Dariya T.
    Popova, Natalya O.
    Goldberg, Victor E.
    Vtorushin, Sergey V.
    Perelmuter, Vladimir M.
    BIOCHEMISTRY-MOSCOW, 2021, 86 (11) : 1461 - 1468
  • [42] Parameters of Tumor Microenvironment Determine Effectiveness of Anti-PD-1/PD-L1 Therapy
    Liubov A. Tashireva
    Dariya T. Muravyova
    Natalya O. Popova
    Victor E. Goldberg
    Sergey V. Vtorushin
    Vladimir M. Perelmuter
    Biochemistry (Moscow), 2021, 86 : 1461 - 1468
  • [43] Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
    Liu, Junjie
    Tao, Haisu
    Yuan, Tong
    Li, Jiang
    Li, Jian
    Liang, Huifang
    Huang, Zhiyong
    Zhang, Erlei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [44] TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
    Yi, Ming
    Li, Tianye
    Niu, Mengke
    Wu, Yuze
    Zhao, Zhenyu
    Wu, Kongming
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [45] Prospects of the potential strategies to improve the efficacy of anti-PD-1/PD-L1 therapy
    Yamaguchi, Hirohito
    Wang, Shao-Chun
    Hung, Mien-Chie
    CLINICAL AND TRANSLATIONAL MEDICINE, 2022, 12 (05):
  • [46] Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
    Su, Chaoyue
    Wang, Hui
    Liu, Yunru
    Guo, Qiaoru
    Zhang, Lingling
    Li, Jiajun
    Zhou, Wenmin
    Yan, Yanyan
    Zhou, Xinke
    Zhang, Jianye
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [47] DNA DAMAGE RESPONSE ALTERATIONS PREDICT RESPONSES TO ANTI-PD-1/PD-L1
    不详
    CANCER DISCOVERY, 2018, 8 (05) : 527 - 527
  • [48] Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies Reply
    Lu, Steve
    Wang, Hao
    Taube, Janis M.
    JAMA ONCOLOGY, 2020, 6 (02) : 299 - 299
  • [49] Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
    Garcia-Aranda, Marilina
    Redondo, Maximino
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (09)
  • [50] Comparison the results from PD-L1 IHC and PD-L1 multiplex immunofluorescence for the prediction of anti-PD-1 immunotherapeutic response
    Sun, Hongzhe
    Liu, Xia
    Jiao, Tao
    Guo, Qian
    Du, Haizhen
    Han, Shuo
    Zhu, Lin
    Zhang, Zhifu
    Kong, Yan
    Li, Na
    CANCER RESEARCH, 2024, 84 (06)